Zeta c-Met Antibody. Zeta’s recombinant rabbit antibody recognizes c‑Met (c-mesenchymal epithelial transition factor), a proto-oncogene tyrosine kinase receptor for hepatocyte growth factor (HGF). The Met proto-oncogene product is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits. The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PIK3 kinase. These fundamental events are important for all the biological functions involving Met kinase activity. The Met proto-oncogene product is a transmembrane receptor-like protein with tyrosine kinase activity that is expressed in many tissues. By immunohistochemistry, c-Met overexpression is present in many types of carcinomas with c-Met gene amplifications. Activating mutations affecting the MET receptor tyrosine kinase are present in several types of human cancers, particularly in papillary renal cell carcinoma, papillary thyroid carcinoma, gastric cancer, and hepatocellular carcinoma.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.